NCT06422247已完成不适用
Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 307 人开始时间: 2024年4月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 307
- 试验地点
- 1
- 主要终点
- Overall survival (OS)
研究概览
简要总结
The purpose of this study is to describe the therapeutic practices and the prognosis of patients with relapsed or refractory peripheral T-cell lymphoma in Japan
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants with a confirmed diagnosis of the specific subtypes of peripheral T-cell lymphoma (PTCL) according to The World Health Organization (WHO) classification of lymphoid neoplasm, 4th edition defined by WHO and International Agency for Research on Cancer (IARC).
- •Participates aged ≥18 years of age at diagnosis of PTCL.
- •Participates who have been treated with a systemic therapy for PTCL and have initiated a systemic therapy as a second-line therapy for relapsed or refractory PTCL between April 1, 2018 and March 31, 2023.
排除标准
- •Participates who have medical history of peripheral T-cell lymphoma (PTCL) treatment by unapproved drug in Japan as of 31 March 2024 or off-label drug for PTCL in Japan as of 31 March
- •Participates who have medical history of participation to a separately defined registration study for regulatory approval in PTCL.
- •Participates who have medical history of PTCL treatment in a separately defined clinical study with intervention by on-label regimen for PTCL.
- •Participates judged to be inappropriate for enrollment in this study by the site investigator.
研究组 & 干预措施
Relapsed or refractory peripheral T-cell lymphoma initiating second-line systemic therapy
干预措施: Systemic therapy (Drug)
结局指标
主要结局
Overall survival (OS)
时间窗: From baseline until date of death from any cause or last known alive date, assessed up to 6 years
次要结局
- Frequency of treatment regimen by treatment line(End date of each treatment-line of therapy, assessed up to 6 years)
- Time to next treatment line or death (TTNT)(From date of first-line therapy initiation until death from any cause or last known alive date, assessed up to 6 years)
- Participant baseline demographics(Baseline)
- Participant baseline clinical characteristics(Baseline)
- Participant treatment sequence from initial diagnosis(From date of initial diagnosis until death from any cause or last known alive date, assessed up to 6 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has SpreadRenal Cell CarcinomaNCT03161145Bristol-Myers Squibb297
暂停
不适用
Study of the therapy, age, complication and outcome for ruptured and unruptured cerebral aneurysm using DPCthe cerebral aneurysmJPRN-UMIN000034242Ministry of Education, Culture, Sports, Science and Technology30,000
已完成
不适用
Multicenter Retrospective Observational Study of Acute Myocarditis in KoreaMyocarditis AcuteNCT05933902Samsung Medical Center841
招募中
不适用
Specialized Treatment, Rehabilitation and Outcome in Patients With Prolonged Critical IllnessCritical IllnessNCT04247607Remeo AB250
Unknown
不适用
Prospective Observational Study Assessing Treatment and Outcomes of Patients With PrediabetesPrediabetesNCT01869101Tethys Bioscience, Inc.560